| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.85.1.305 |
| P953 | full work available at URL | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.85.1.305 |
| P698 | PubMed publication ID | 1728462 |
| P2093 | author name string | H. Pannekoek | |
| M. Levi | |||
| ten Cate JW | |||
| van Zonneveld AJ | |||
| J. W. ten Cate | |||
| B. J. Biemond | |||
| A. J. van Zonneveld | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood coagulation | Q179217 |
| Cardiology and cardiovascular medicine | Q96320350 | ||
| plasminogen | Q107129060 | ||
| thrombosis | Q261327 | ||
| thrombolysis | Q1931577 | ||
| P304 | page(s) | 305-312 | |
| P577 | publication date | 1992-01-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis | |
| P478 | volume | 85 |
| Q43151596 | Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. |
| Q35747706 | Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging |
| Q24310458 | Anticoagulant and antithrombotic properties of platelet protease nexin-1 |
| Q43185376 | Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis |
| Q73940083 | Association of hemostatic factors with peripheral vascular disease |
| Q35833573 | Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells |
| Q47772414 | Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. |
| Q27675149 | Characterization of a Small Molecule Inhibitor of Plasminogen Activator Inhibitor Type 1 That Accelerates the Transition into the Latent Conformation |
| Q73360690 | Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate |
| Q33502675 | Current drug treatment strategies for disseminated intravascular coagulation |
| Q33371584 | Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model |
| Q43117440 | Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis |
| Q44518810 | Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. |
| Q90142206 | Engineered microparticles and nanoparticles for fibrinolysis |
| Q73705922 | Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator |
| Q51068066 | Eplerenone reduces arterial thrombosis in diabetic rats. |
| Q33504864 | Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits |
| Q40582633 | Fibrinolysis and thrombosis |
| Q73886817 | Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects |
| Q34006140 | Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence |
| Q58863655 | In vivo veritas: Thrombosis mechanisms in animal models |
| Q35764729 | Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha |
| Q71901188 | Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp |
| Q40452547 | Is Familial Mediterranean Fever a thrombotic disease or not? |
| Q33700633 | Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells |
| Q41735648 | Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs |
| Q47793711 | Myocardial infarction occurs with a similar 24 h pattern in the 4G/5G versions of plasminogen activator inhibitor-1. |
| Q73107303 | Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms |
| Q44088573 | Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazines |
| Q33337844 | Osteonecrosis induced by a single administration of low-dose lipopolysaccharide in rabbits |
| Q34220031 | Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro |
| Q36039212 | Pivotal role of plasminogen-activator inhibitor 1 in vascular disease |
| Q33790622 | Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure |
| Q33832519 | Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity |
| Q73295877 | Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance |
| Q35688843 | Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance |
| Q34384932 | Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents |
| Q40305997 | Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis |
| Q35450594 | Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow |
| Q33845781 | Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis |
| Q33984228 | Pleiotropic functions of plasminogen activator inhibitor-1. |
| Q73295825 | Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors |
| Q77295577 | Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction |
| Q73999113 | Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction |
| Q54628759 | Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. |
| Q33950656 | Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance |
| Q28272554 | Role of vitronectin and its receptors in haemostasis and vascular remodeling |
| Q32037411 | Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries |
| Q36456292 | Surface modification of PVDF using non-mammalian sources of collagen for enhancement of endothelial cell functionality. |
| Q58106436 | Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice |
| Q73579431 | T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats |
| Q83306169 | The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction |
| Q43264477 | The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice |
| Q45842157 | The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood |
| Q40894566 | The status of plasminogen activator inhibitor-1 as a therapeutic target |
| Q35684759 | Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis |
| Q49558417 | Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1 (PAI-1). |
| Q36868343 | VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. |
| Q37802497 | Venous Thromboembolic Disease and Hematologic Considerations in Obesity |
| Q73130642 | YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice |
| Q41228470 | α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis |
Search more.